硼替佐米联合地塞米松方案治疗多发性骨髓瘤分析  

Analysis of velcade combined with dexamethasone regimen treating multiple myeloma

作　　者：庞丽萍[1] 陈甜甜[2] 徐海婵[1] 钟凤鸾[1] 许蕾[1] 张文丽[1] 孟庆祥[1] 

机构地区：[1]北京大学深圳医院血液科,518036 [2]深圳市中医院检验科

出　　处：《中国医药》2013年第1期76-77,共2页China Medicine

摘　　要：目的探讨硼替佐米联合地塞米松（VD）方案治疗多发性骨髓瘤（MM）的疗效及安全性。方法回顾分析我科诊断的11例MM患者的临床资料，均为初诊MM患者，采用VD方案治疗1—3个疗程，继之以长春新碱联合阿霉素和地塞米松（VAD）方案化疗1～4个疗程，达平台期后以沙利度胺加泼尼松、马法兰维持治疗。结果11例患者中位随访时间24个月，VD方案1个疗程完全缓解5例，接近完全缓解2例，部分缓解4例。主要不良反应：末梢神经麻木1例，躁动、多语2例，肺部感染加重并真菌感染2例，腹泻1例，带状疱疹2例。结论VD方案治疗初诊MM疗效肯定，安全性尚好，可作为MM的首选治疗方案。Objective To explore the efficiency and safety of velcade regimen treating multiple myeloma （MM）. Methods Totally 11 MM patients during August 2008 to May 2011 treated with VD regimen were analyzed retrospectively. VD regimen was adopted. Then VAD regimen was used. Halidomide combined with prednisone and mafalan were given during stable stage. Results The median follow-up period was 24 months. After one VD course, the main side effects were as follow： one peripheral nerve numbness, two restless multilingual, two lung infection （bacter and fungal） , one diarrhea and two zoster. Conclusions VD regimen can be used to treat MM.

关 键 词：多发性骨髓瘤 硼替佐米 疗效比较研究 

分 类 号：R551[医药卫生—血液循环系统疾病]